Bavarian Nordic is now catching up to Valneva, whose Ixchiq vaccine became the world’s first licensed chikungunya vaccine ...

(RTTNews) - Valneva SE (VALN) a specialty vaccine company, on Wednesday announced that it is advancing to a Phase 3 trial for IXCHIQ, its single-dose chikungunya vaccine, in children aged 1 to 11 ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved Valneva’s single-dose chikungunya vaccine for use in adults. Ixchiq is now the first vaccine approved in the UK to prevent ...

The UK approval marks the fourth regulatory approval Valneva has received for its single-shot chikungunya vaccine. The vaccine is currently approved in the United States (U.S.) 2, Europe 3 and Canada ...

Marketing authorization for the first EU vaccine to protect adolescents against chikungunya has been expedited for its public ...

for the world’s first and only chikungunya vaccine, Ixchiq. The single-dose vaccine is indicated for active immunization for the prevention of disease caused by chikungunya virus (CHIKV) in ...

Valneva’s chikungunya vaccine Ixchiq has been greenlit by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA), allowing the single-dose vaccine to be made available for adults.

Valneva has received Medicines and Healthcare products Regulatory Agency (MHRA) authorisation in the UK for the world’s first - and only - Chikungunya vaccine, IXCHIQ. The single-dose vaccine is ...

Valneva (VALN) announced that the Medicines and Healthcare products Regulatory Agency or MHRA has granted marketing authorization in the United ...

1 Valneva Reports Positive Three-Year Antibody Persistence Data for its Single-Shot Chikungunya Vaccine IXCHIQ® - Valneva 2 Valneva Announces U.S. FDA Approval of World's First Chikungunya ...